Monsanto´s business in Europe is very strong and growing. In order to better serve farmers in Europe we will be investing several hundred million dollars in Europe over a decade to expand our conventional seed production and breeding. In parallel, biotech crops are highly successful in the rest of the world. In order to fully support both of these success stories, we will no longer be pursuing approvals for cultivation of new biotech crops in Europe. Instead, we will focus on enabling imports of biotech crops into the EU and the growth of our current business there.
Our decision impacts all our pending applications except for MON 810 which we will retain. However, we are doing a careful analysis application by application considering our obligations to business partners and this will inform which files will be withdrawn and when.